Atossa Therapeutics Inc. (NASDAQ: ATOS)
$1.41
+0.0100 ( +0.71% ) 125.1K
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Market Data
Open
$1.41
Previous close
$1.40
Volume
125.1K
Market cap
$177.95M
Day range
$1.39 - $1.43
52 week range
$0.62 - $2.31
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | May 13, 2024 |
10-q | Quarterly Reports | 64 | May 13, 2024 |
ars | Annual reports | 1 | May 10, 2024 |
pre | Proxies and info statements | 8 | May 10, 2024 |
4 | Insider transactions | 1 | Apr 11, 2024 |
8-k/a | 8K-related | 12 | Apr 02, 2024 |
8-k | 8K-related | 12 | Apr 01, 2024 |
10-k | Annual reports | 76 | Apr 01, 2024 |
8-k | 8K-related | 11 | Mar 18, 2024 |
4 | Insider transactions | 1 | Mar 14, 2024 |